The efficacy of Apaziquone in the treatment of bladder cancer

References

• Antoni S, Ferlay J, Soerjomataram I, et al. Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol. 2017 Jan;71(1):96–108.
   PubMed Web of Science ®Google Scholar
• Burger M, Catto JW, Dalbagni G, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013;63:234.
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, Van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49:466.
   PubMed Web of Science ®Google Scholar
• Babjuk M, Böhle A, Burger M, et al. EAU Guidelines on Non-Muscle Invasive Urothelial Carcinoma of the Bladder. Update 2016. Eur Urol. 2017 Mar;71(3):447–461.
   Google Scholar
• Naito S, Algaba F, Babjuk M, et al. The Clinical Research Office of the Endourological Society (CROES) multicentre randomised trial of narrow band imaging-assisted Transurethral Resection of Bladder Tumour (TURBT) versus conventional white light imaging-assisted TURBT in primary non-muscle-invasive bladder cancer patients: trial protocol and 1-year results. Eur Urol. 2016;70(3):506–515.
   PubMed Web of Science ®Google Scholar
• Stenzl A, Jocham D, Jichlinski P, et al. Photodynamic diagnostics in the urinary tract. Consensus paper of the Working Group for Oncology of the German Society for Urology. Urologe A. 2008 Aug;47(8):982–987.
   PubMedGoogle Scholar
• Pawinski A, Sylvester R, Kurth KH, et al. A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Party on Superficial Bladder Cancer. J Urol. 1996 Dec;156(6):1934–1940; discussion 1940–1931.
   PubMed Web of Science ®Google Scholar
• Sangeda RZ, Vandepitte J, Hygens A, et al. Prevention of tumor cell reimplantation during transurethral resection: te in-vitro antiadhesive and cytotoxic properties of an irrigant containing polyethylene glycol 400. Anticancer Drugs. 2010 Jul;21(6):645–650.
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, Oosterlinck W, Van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol. 2004;171:2186.
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, Oosterlinck W, Holmang S, et al. Systematic review and individual patient data meta-analysis of randomized trials comparing a single immediate instillation of chemotherapy after transurethral resection with transurethral resection alone in patients with stage pTa-pT1 urothelial carcinoma of the bladder: which patients benefit from the instillation? Eur Urol. 2015. http://www.ncbi.nlm.nih.gov/pubmed/26091833.
   Web of Science ®Google Scholar
• Sylvester RJ, Oosterlinck W, Witjes JA. 2008. The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials. Eur Urol. 2008 Apr;53:709–719.
   Google Scholar
• Bouffioux C, Kurth KH, Bono A, et al. Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. European Organization for Research and Treatment of Cancer Genitourinary Group. J Urol. 1995;153:934.
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, Van der Meijden A, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol. 1964;2002(168):1964–1970.
   Google Scholar
• Malmström PU, Sylvester RJ, Crawford DE, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for nonmuscle- invasive bladder cancer. Eur Urol. 2009;56:247.
   PubMed Web of Science ®Google Scholar
• Cambier S, Sylvester RJ, Collette L, et al. EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 Urothelial bladder cancer patients treated with 1-3 years of maintenance bacillus calmette-guerin. Eur Urol. 2016 Jan;69(1):60–69.
   PubMed Web of Science ®Google Scholar
• Hendricksen K, Witjes JA. Current strategies for first and second line intravesical therapy for nonmuscle invasive bladder cancer. Curr Opin Urol. 2007;17:352–357.
   PubMed Web of Science ®Google Scholar
• Tomaszewski JJ, Smaldone MC. Emerging intravesical therapies for management of nonmuscle invasive bladder cancer. Open Access J Urol. 2010;2:67–84.
   PubMedGoogle Scholar
• Svatek RS, Kamat AM, Dinney CP. Novel therapeutics for patients with non-muscle-invasive bladder cancer. Expert Rev Anticancer Ther. 2009;9(6):807–813.
   PubMed Web of Science ®Google Scholar
• Lammers RJ, Witjes JA, Inman BA, et al. The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: a systematic review. Eur Urol. 2011;60:81.
   PubMed Web of Science ®Google Scholar
• Di Stasi SM, Giannantoni A, Giurioli A, et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol. 2006 Jan;7(1):43–51.
   PubMed Web of Science ®Google Scholar
• Lammers RJM, Witjes WPJ, Mhd J-P, et al. Intracutaneous and intravesical immunotherapy with keyhole limpet hemocyanin compared with intravesical mitomycin in patients with non-muscle-invasive bladder cancer: results from a prospective randomized phase III trial. W A J Clin Oncol. 2017;30(18):2273–2279.
   Web of Science ®Google Scholar
• Ferreira-Teixeira M, Paiva-Oliveira D, Parada B, et al. Natural killer cell-based adoptive immunotherapy eradicates and drives differentiation of chemoresistant bladder cancer stem-like cells. BMC Med. 2016;1–13. DOI:10.1186/s12916-016-0715-2.
   PubMed Web of Science ®Google Scholar
• Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell. 2015;161:2015–2214.
   Web of Science ®Google Scholar
• Ramesh N, Ge Y, Ennist DL, et al. CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor armed oncolytic adenovirus for the treatment of bladder cancer. Clin Cancer Res. 2006;12(1):305–313.
   PubMed Web of Science ®Google Scholar
• Packiam VT, Johnson SC, Steinberg GD. Non-muscle-invasive bladder cancer: intravesical treatments beyond bacille Calmette-Guérin. Cancer. 2017 Feb 1;123(3):390–400.
   Google Scholar
• Apaziquone for treatment of patients with non-muscle-invasive bladder cancer following trasurethral resection of bladder tumors. Spectrum Pharmaceuticals, Inc. Apaziquone ODAC Briefing Book. 2016. Available from: https://www.fda.gov/…/Drugs/OncologicDrugsAdvisoryCommitte.
   Google Scholar
• González González D, Haitze Van der Veen J, Ypma AF, et al. Brachytherapy for urinary bladder cancer. Arch Esp Urol. 1999 Jul-Aug;52(6):655–661.
   PubMedGoogle Scholar
• Guise CP, Mowday AM, Ashoorzadeh A, et al. Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia. Chin J Cancer. 2014;33(2):80–86.
   PubMed Web of Science ®Google Scholar
• Walton MI, Smith PJ, Workman P. The role of NAD(P)H: quinone reductase (EC 1.6.99.2, DT-diaphorase) in the reductive bioactivation of the novel indoloquinone antitumor agent EO9. Cancer Commun. 1991;3:199.
   PubMed Web of Science ®Google Scholar
• Van der Schoot SC, Vainchtein LD, Nuijen B, et al. Purity profile of the indoloquinone anticancer agent EO-9 and chemical stability of EO-9 freeze dried with 2-hydroxypropyl-B-cyclodextrin. Pharmazie. 2008;63:11.
   Web of Science ®Google Scholar
• Loadman PM, Bibby MC, Phillips RM. Pharmacological approach towards the development of indolequinone bioreductive drugs based on the clinically inactive agent EO9. Br J Pharmacol. 2002;137(5):701–709.
   PubMed Web of Science ®Google Scholar
• Choudry GA, Hamilton Stewart PA, Double JA, et al. A novel strategy for NQO1 (NAD(P)H: quinone oxidoreductase, EC 1.6.99.2) mediated therapy of bladder cancer based on the pharmacological properties of EO9. Br J Cancer. 2001;85(8):1137–1146.
   PubMed Web of Science ®Google Scholar
• Schellens JH, Planting AS, Van Acker BA, et al. Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylant cytotoxic drug EO9. J Natl Cancer Inst. 1994 Jun 15;86(12):906–912.
   PubMedGoogle Scholar
• Phillips RM, Hendriks HR, Peters GJ. EO9 (Apaziquone): from the clinic to the laboratory and back again. Br J Pharmacol. 2013;168(1):11–18. DOI:10.1111/j.1476-5381.2012.01996.x.
   PubMed Web of Science ®Google Scholar
• Vainchtein LD, Rosing H, Mirejovsky D, et al. Stability experiments in human urine with EO9 (apaziquone): a novel anticancer agent for the intravesical treatment of bladder cancer. J Pharm Biomed Anal. 2007;43:285–292.
   PubMed Web of Science ®Google Scholar
• Gofrit ON, Zorn KC, Shikanov S, et al. Marker lesion experiments in bladder cancer - what have we learned?. J Urol. 2010;183:1678–1685.
   PubMed Web of Science ®Google Scholar
• Van der Heijden AG, Moonen PMJ, Cornel EB, et al. Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response. J Urol. 2006;176(4):1349–1353. DOI:10.1016/j.juro.2006.06.007.
   PubMed Web of Science ®Google Scholar
• Jain A, Phillips RM, Scally AJ, et al. Response of multiple recurrent TaT1 bladder cancer to intravesical Apaziquone (EO9): comparative analysis of tumor recurrence rates. Urology. 2009;73(5):1083–1086.
   PubMed Web of Science ®Google Scholar
• Pharmaceuticals S. Spectrum Pharmaceuticals, Inc. Apaziquone ODAC briefing book. 2016. [cited 2016 Sep 14]. Available from: https://www.fda.gov/downloads//Drugs/UCM520094.pdf
   Google Scholar
• Hendricksen K, Cornel EB, Reijke D, et al. Phase 2 study of adjuvant intravesical instillations of apaziquone for high-risk non-muscle invasive bladder cancer. J Urol. 2012;187(4):1195–1199. DOI:10.1016/j.juro.2011.11.101.
   PubMed Web of Science ®Google Scholar
• Karsh L, Shore N, Saltzstein D, et al. Integrated results of two multicenter, randomised, placebo controlled, double blind, phase 3 trials (SPI-611/612) of single dose intravesical Apaziquone immediately following resection in patients with nonmuscle invasive bladder cancer. J Urol. 2016;95(Supplement):e290.
   Google Scholar
• Witjes JA, Karsh L, Soloway M, et al. Improved efficacy of adjuvant, single dose intravesical Apaziquone by timing post-resection in two double blind, randomised, placebo-controlled phase 23 studies in non-muscle invasive bladder cancer. J Urol. 2016;195(Supplement):e136.
   Google Scholar